^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Puyouheng (pucotenlimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
Published date:
12/31/2020
Excerpt:
In patients with PD-L1-positive tumors, ORR and DCR were 75% (9/12) and 83.3% (10/12), respectively, whereas in patients with PD-L1-negative tumors, ORR and DCR were 66.7% (6/9) and 100% (9/9), respectively….In conclusion, HX008 in combination with oxaliplatin and capecitabine demonstrated an acceptable safety profile and promising anti-tumor activity as first-line treatment in Chinese patients with advanced G/GEJ cancer.
Secondary therapy:
capecitabine + oxaliplatin
DOI:
10.1080/2162402X.2020.1864908
Source:
Title:
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
Excerpt:
Between October 2018 and September 2019, a total of 58 patients with advanced G/GEJ cancer were enrolled in this study… ORR in patients with PD-ligand 1 (L1) positive (Combined Positive Score (CPS) ≥1) and negative (CPS＜1) tumors was 38.5% (5/13) and 37.5% (3/8), respectively... Patients with PD-L1 positive tumors tended to have longer OS than those with PD-L1 negative tumors, but the difference was not statistically significant (NR vs 8.7 months, p=0.1858).
Secondary therapy:
irinotecan
DOI:
http://dx.doi.org/10.1136/jitc-2020-001279
Trial ID:
